Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Considerations for CPX-351 in Acute Myeloid Leukemia

January 19th 2018

Promise of Recently Approved Agents for AML: CPX-351

January 19th 2018

Debating an Algorithm for Molecular Testing in AML

January 19th 2018

Recommended Molecular Testing in Acute Myeloid Leukemia

January 19th 2018

The Microenvironment and Epigenetics in AML

January 19th 2018

Acute Myeloid Leukemia: Understanding Biologic Drivers

January 19th 2018

Dr. Chapman on Targeted Treatments for Non-Traditional Mutations in Melanoma

January 18th 2018

Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

January 15th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

FDA Expands Afatinib's Approval for Lung Cancer

January 14th 2018

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer

January 12th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

January 11th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

The Future Treatment of Follicular Lymphoma

January 5th 2018

Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018